CagriSema Diabetes Data Debuts at ADA 2026

Novo Nordisk will unveil the first detailed results from its REIMAGINE Phase 3 program — CagriSema in adults with type 2 diabetes — at the American Diabetes Association's 86th Scientific Sessions in New Orleans on Sunday, June 7, 2026. This is the diabetes counterpart to the REDEFINE obesity trials, and it answers a question buyers have been circling for months: how well does the amylin/GLP-1 combination work when the patient already has diabetes, not just excess weight?

Research-context information only. CagriSema is an investigational fixed-dose combination not approved by the FDA. The data below come from Novo Nordisk press disclosures and conference previews. Cagrilintide and semaglutide sold by research peptide vendors are not approved for human use, and possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what was published — not what should be done. Consult a licensed physician for personal medical decisions.

What REIMAGINE Is Testing

REIMAGINE is a three-trial Phase 3 program evaluating CagriSema — a once-weekly fixed-dose combination of cagrilintide 2.4 mg (a long-acting amylin analog) and semaglutide 2.4 mg — specifically in people with type 2 diabetes. The session at ADA 2026, "REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema," runs Sunday June 7 from 4:30–6:00 p.m. in Great Hall A, chaired by John B. Buse, MD, PhD.

The three trials cover three real-world treatment positions:

• REIMAGINE 1 — CagriSema as monotherapy in drug-naive patients who have not adequately responded to lifestyle changes. Includes a 12-week off-drug period to test how durable the effect is after stopping.
• REIMAGINE 2 — CagriSema versus its individual components and placebo in patients already on metformin (with or without an SGLT2 inhibitor). This is the workhorse trial: 2,728 adults, mean baseline HbA1c 8.2%, mean baseline weight 101 kg.
• REIMAGINE 3 — CagriSema added on top of basal insulin therapy, the hardest-to-treat group.

Topline numbers released earlier in 2026 from REIMAGINE 2 set expectations: CagriSema cut HbA1c by up to 1.91 percentage points and reduced body weight by up to 14.2% over 68 weeks, beating both cagrilintide alone and semaglutide alone on glycemic control and weight. The full per-dose breakdowns, responder rates, and safety tables are what land at ADA on June 7.

Sources: ADA Meeting News REIMAGINE preview | Healio: CagriSema superior to semaglutide at 68 weeks | Lilly/ADA 2026 session schedule.

Diabetes Numbers vs Obesity Numbers — Why the Gap Matters

The single most useful thing to understand about REIMAGINE is that its weight-loss numbers are lower than CagriSema's obesity numbers, and that is expected, not a failure. Diabetes consistently blunts GLP-1-class weight loss — people with type 2 diabetes lose roughly two-thirds of what non-diabetic patients lose on the same drug.

For comparison, in REDEFINE 1 the combination beat its components cleanly: CagriSema 22.7% versus semaglutide alone 16.1% and cagrilintide alone 11.8%. REIMAGINE 2 reproduces that ordering in a diabetic population — the combination still wins, just at a lower absolute level. A 14.2% weight loss with a 1.91-point A1C reduction is a strong diabetes result; for context, semaglutide 2.4 mg alone typically delivers single-digit weight loss and roughly a 1.5-point A1C drop in diabetic patients.

The mechanism behind the gap is the same reason CagriSema exists at all: stacking cagrilintide's amylin signaling on top of semaglutide's GLP-1 signaling hits two separate satiety pathways. Amylin slows gastric emptying and acts on the hindbrain to extend fullness; GLP-1 suppresses appetite and improves insulin secretion. Two levers, more weight loss — even when diabetes is dampening the response.

What This Means If You Are Sourcing Now

CagriSema is not FDA approved and is not sold as a finished combination product anywhere legitimate. Novo Nordisk is widely expected to file CagriSema with the FDA during 2026, with a possible approval decision in 2027 — meaning a year-plus before any pharmacy can dispense it, and that is for the obesity indication first; the diabetes indication typically follows. Until then, the only routes are clinical trials or research peptide vendors selling the two components separately.

If you are sourcing the components for research, the practical reality is that cagrilintide is the harder one to buy well. Semaglutide is mature, widely stocked, and easy to find with current COAs. Cagrilintide is newer, less commonly stocked, and quality varies more — third-party HPLC and mass-spec verification matters more here. Look for vendors that publish recent Janoshik or Anresco results for cagrilintide specifically, not just a generic vendor-wide certificate.

Compare live in-stock options and COA notes at /best/cagrilintide and /best/semaglutide, and check the current coupon stack at /deals/ before ordering.

How CagriSema Differs From Tirzepatide and Retatrutide

CagriSema is often lumped in with the GIP-containing combos, but it is mechanistically distinct. It pairs GLP-1 with amylin, not GIP or glucagon:

The takeaway: in obesity, CagriSema and tirzepatide sit roughly tied, with retatrutide on top. In diabetes, CagriSema's 14.2% is competitive with tirzepatide's diabetic weight loss while also delivering a strong A1C reduction. Amylin is the differentiator — it is the first time a clinically validated amylin analog has been stacked with a GLP-1 in a fixed-dose Phase 3 program, and REIMAGINE is the cleanest read yet on what that pairing does in diabetes.

For the full mechanism breakdown and the obesity-side comparison, see our cagrilintide vs semaglutide guide and the CagriSema vs CagriTirz analysis.

Side Effects: GI Class Effects, Watch Nausea on Escalation

CagriSema's safety profile in the REDEFINE and Lancet Phase 2 work has been consistent with the GLP-1 class — gastrointestinal events (nausea, vomiting, diarrhea, constipation) are the most common adverse events, predominantly mild to moderate, and concentrated during dose escalation. Adding amylin does not appear to introduce a new category of side effect, but it can intensify early GI tolerability issues, which is why slow titration is built into the dosing.

Full REIMAGINE safety tables — discontinuation rates, hypoglycemia incidence in the insulin add-on arm, and the off-drug rebound data from REIMAGINE 1 — are part of the June 7 ADA presentation. The insulin-combination arm (REIMAGINE 3) is the one to watch for hypoglycemia signal, since stacking on basal insulin raises that risk independent of the peptides.

For the component-level side-effect detail, see our cagrilintide dosing guide and semaglutide side effects article.